| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/10/2005 | US20050033024 Expression vector comprising nucleotide sequences coding cytokine receptor for use as tool in identifying modulators for prevention and treatment allergic, skin and respiratory disorders |
| 02/10/2005 | US20050033017 Nucleotide sequences coding receptor for advanced glycation endproducts (RAGE) for identifying modulators for treatment and prevention of cell proliferative and cardiovascular disorders |
| 02/10/2005 | US20050032890 Aniline-derived ligands for the thyroid receptor |
| 02/10/2005 | US20050032841 Enzyme inhibitors of ceramide glucosyltransferase or agents capable of increasing the rate of neuronal glycolipid degradation in treating of mucopolysaccharidosis diseases; e.g., N-butyldeoxynojirimycin and other imino sugars and genetic approaches; synergistic effect on activity of glucocerebrosidase |
| 02/10/2005 | US20050032827 Sigma ligands for neuronal regeneration and functional recovery |
| 02/10/2005 | US20050032733 siNA molecule comprising a double-stranded structure that down-regulates expression of Hepatitis B Virus (HBV) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 02/10/2005 | US20050032730 Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions |
| 02/10/2005 | US20050032728 Tumor suppression through bicistronic co-expression of p53 and p14ARF |
| 02/10/2005 | US20050032727 Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways |
| 02/10/2005 | US20050032726 Protein kinase (PK); for increasing the susceptibility of a cell to DNA-damaging agents via hybridization of nucleic acids encoding DNA dependent protein kinases, preventing gene expression; genetic engineering |
| 02/10/2005 | US20050032725 useful in the diagnosis, treatment or prevention of conditions characterized by a too-vigorous effector T cell response to antigens |
| 02/10/2005 | US20050032724 Multidrug Resistance Protein 1 (MRP1); mutagenesis |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032722 Soluble steroidal peptides for nucleic acid delivery |
| 02/10/2005 | US20050032721 Methods of administering dalbavancin for treatment of skin and soft tissue infections |
| 02/10/2005 | US20050032714 immunotherapeutic for therapy and prophylaxis of cancer; reduced duration, less toxicity, and as thus results in improved tolerance |
| 02/10/2005 | US20050032709 Anti-hypertensive molecules and process for preparation thereof |
| 02/10/2005 | US20050032708 up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursors (N-acetyl cysteine); for treating neuropsychiatric disorder like schizophrenia, psychosis, bipolar disorder, manic depression, affective disorder, drug induced psychosis, delirium |
| 02/10/2005 | US20050032707 Novel peptides comprising furanoid sugar amino acids for the treatment of cancer |
| 02/10/2005 | US20050032706 Hypoglycaemic peptides and methods of use thereof |
| 02/10/2005 | US20050032705 Alpha-conotoxin peptides |
| 02/10/2005 | US20050032704 Neural thread proteins (NTP); antiproliferative agents |
| 02/10/2005 | US20050032703 Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof |
| 02/10/2005 | US20050032702 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 02/10/2005 | US20050032701 Use of calmodulin to promote bone regeneration |
| 02/10/2005 | US20050032700 Polypeptide for use in the treatment of tumors, diabetes and arteriolosclerosis |
| 02/10/2005 | US20050032699 Composition of a VEGF antagonist and an anti-proliferative agent |
| 02/10/2005 | US20050032698 includes a divalent cation (zinc chloride) in an amount effective to stabilize the hormone; osteoporosis |
| 02/10/2005 | US20050032697 Heparin binding VEGFR-3 ligands |
| 02/10/2005 | US20050032696 Muscle transcription factors |
| 02/10/2005 | US20050032695 screening drugs for treatment of pain |
| 02/10/2005 | US20050032694 Neurotrypsin |
| 02/10/2005 | US20050032693 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 02/10/2005 | US20050032692 Methods of inhibiting tumor cell proliferation |
| 02/10/2005 | US20050032691 Methods for treating glaucoma |
| 02/10/2005 | US20050032690 Intravenous, subcutaneous, intradermal, or intramuscular administration; proteolysis |
| 02/10/2005 | US20050032689 Methods for treatment or diagnosis of disease or disorders associated with an APB domain |
| 02/10/2005 | US20050032688 Use of angiotensin II fragments and analogs thereof in tissue repair |
| 02/10/2005 | US20050032687 Glucose-6-phosphate dehydrogenase; antitumor agents; for treatment of (rheumatic) arthritis |
| 02/10/2005 | US20050032686 administering to a manimal a therapeutically effective amount of ES-62 ( a glycoprotein) to treat an inflammatory disease: arthritis and chronic obstructive pulmonary disease |
| 02/10/2005 | US20050032685 Remedies for bone loss |
| 02/10/2005 | US20050032684 Use of a peptide which activates guanylate-cyclase c for the treatment of respiratory airway problems via the airways, medicament, inhaltion devices and method of diagnosis |
| 02/10/2005 | US20050032683 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 02/10/2005 | US20050032682 Contains erythropoietin, which protectively acts on survival of oligodendrocytes, which form myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease |
| 02/10/2005 | US20050032681 Human antithrombin iiis and methods related thereto |
| 02/10/2005 | US20050032680 Method of treatment of vulval vestibulitis |
| 02/10/2005 | US20050032679 Process for the preparation of echinocandin derivatives |
| 02/10/2005 | US20050032676 Administering lipidated glycopeptide antibiotic and cyclodextrin, reduced tissue accumulation of the glycopeptide antibiotic, reduced nephrotoxicity and reduced histamine release |
| 02/10/2005 | US20050032675 Galectin inhibitors such as fetuin; competitive binding; glycoproteins |
| 02/10/2005 | US20050032674 SAIF, an anti-inflammatory factor, and methods of use thereof |
| 02/10/2005 | US20050032673 Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease |
| 02/10/2005 | US20050032221 Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof |
| 02/10/2005 | US20050032219 Methods of administering vectors to synaptically connected neurons |
| 02/10/2005 | US20050032214 Cell-specific expression/replication vector |
| 02/10/2005 | US20050032190 Beta-secretase substrates and uses thereof |
| 02/10/2005 | US20050032189 Novel protein derived from agkistrodon saxatilis emelianov and process preparing the same |
| 02/10/2005 | US20050032170 Expression vector comprising nucleotide sequences coding native sequence-4 (NS4) for use in identifying modulators for treatment and prevention of obesity, cachexia and anorexia |
| 02/10/2005 | US20050032168 17 human secreted proteins |
| 02/10/2005 | US20050032161 Novel xanthine phosphoribosyl transferase |
| 02/10/2005 | US20050032155 Expression vector comprising nucleotide sequences coding defective receptor protein for use as model in treatment and prevention of convulsive disorders |
| 02/10/2005 | US20050032134 Neoplasm-specific polypeptides and their uses |
| 02/10/2005 | US20050032131 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 02/10/2005 | US20050032123 Oncoprotein protein kinase |
| 02/10/2005 | US20050032094 Promoter sequences for specialized polymerase for use in diagnosis, prevention and treatment of cell proliferative and aging disorders |
| 02/10/2005 | US20050032079 Antibodies immunologically specific for PD2, a protein that is amplified and overexpressed in pancreatic cancer |
| 02/10/2005 | US20050032073 Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals |
| 02/10/2005 | US20050032062 Methods for the assessment and prognosis of sarcoidosis |
| 02/10/2005 | US20050032039 HIV-specific T-cell induction |
| 02/10/2005 | US20050031704 Tricalcium phosphates, their composites, implants incorporating them, and method for their production |
| 02/10/2005 | US20050031698 Hydroxyapatite/collagen (HAp/Col) nanocomposite; a bioabsorbable capsule capable of enclosing growth factor, DNA enzyme therein |
| 02/10/2005 | US20050031694 Methods for promoting growth of bone, ligament, and cartilage using zvegf4 |
| 02/10/2005 | US20050031675 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/10/2005 | US20050031665 Orthopedic hardware with a sustained release device configured to release a compound over an extended period of time and is attachable to a portion of the body |
| 02/10/2005 | US20050031648 Locally administering a botulinum neurotoxin to a cancer or to the vicinity of the afflicted atypical tissue |
| 02/10/2005 | US20050031642 Clonal lentogenic oncolytic strain of Newcastle Disease Virus and hemaglutinin-neuraminidase (HN) gene |
| 02/10/2005 | US20050031638 Vaccine |
| 02/10/2005 | US20050031635 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen |
| 02/10/2005 | US20050031634 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 02/10/2005 | US20050031631 Parietaria judaica ns-ltp antigen variants, uses thereof and compositions comprising them |
| 02/10/2005 | US20050031629 An immunogenic A beta fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A beta fragment; Alzheimer's disease; antibodies |
| 02/10/2005 | US20050031628 Chimeric antigens for breaking host tolerance to foreign antigens |
| 02/10/2005 | US20050031608 Modified alpha-neurotoxins as painkillers |
| 02/10/2005 | US20050031607 Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots |
| 02/10/2005 | US20050031606 Lyase treatment for P. carinii |
| 02/10/2005 | US20050031605 Compositions and methods of treating diabetes |
| 02/10/2005 | US20050031604 Secreted by serpent venom glands; endogenous vasopeptidase inhibitors; angiotensin converting enzyme inhibitors; vasodilating and anti-hypertensive action; bradykinins; mass spectrometry |
| 02/10/2005 | US20050031603 Obtainable from whey fraction of milk curd; centrifugation; ultrafiltration; lyophilization |
| 02/10/2005 | US20050031602 Composition with heart rate reducing properties |
| 02/10/2005 | US20050031599 Method of isolating retinal stem cells and inducing retinal stem cells to produce retinal cells; retinal stem cell and retinal cell culture systems may be used for toxicological assays, for isolating genes involved in retinal differentiation or for developing tumor cell lines |
| 02/10/2005 | US20050031595 Ex-vivo expanding a population of stem cells, while inhibiting differentiation of the stem cells using a transition metal compound that chelates copper such as tetraethylenepentamine |
| 02/10/2005 | US20050031590 Adenoviral vectors having a protein IX deletion |
| 02/10/2005 | US20050031589 Method of treating hepatitis C infection |
| 02/10/2005 | US20050031588 2'-branched nucleosides and Flaviviridae mutation |
| 02/10/2005 | US20050031587 Immune response induction method |
| 02/10/2005 | US20050031586 Method for treating hepatitis c virus infection in treatment failure patients |
| 02/10/2005 | US20050031585 Treating individuals having hepatitis C virus infection, who have failed to respond to therapy with IFN-alpha other than consensus interferon (CIFN), or who, following cessation of therapy with IFN-alpha other than CIFN, have suffered relapse by administering first, then second dosing CIFN, and ribavirin |
| 02/10/2005 | US20050031584 Interleukin-2:remodeling and glycoconjugation of interleukin-2 |
| 02/10/2005 | US20050031583 Uses of opg to modulate immune responses |
| 02/10/2005 | US20050031582 Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors |
| 02/10/2005 | US20050031549 Compositions and methods for enhanced mucosal delivery of growth hormone |